Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) EBT Margin (2016 - 2025)

Celldex Therapeutics has reported EBT Margin over the past 16 years, most recently at 67204.13% for Q4 2025.

  • Quarterly results put EBT Margin at 67204.13% for Q4 2025, down 6319630.0% from a year ago — trailing twelve months through Dec 2025 was 16737.19% (down 1448843.0% YoY), and the annual figure for FY2025 was 16748.03%, down 1449927.0%.
  • EBT Margin for Q4 2025 was 67204.13% at Celldex Therapeutics, down from 7753.42% in the prior quarter.
  • Over the last five years, EBT Margin for CLDX hit a ceiling of 384.28% in Q2 2021 and a floor of 67204.13% in Q4 2025.
  • Median EBT Margin over the past 5 years was 6032.34% (2021), compared with a mean of 10230.76%.
  • Peak annual rise in EBT Margin hit 1329034bps in 2025, while the deepest fall reached -6319630bps in 2025.
  • Celldex Therapeutics' EBT Margin stood at 6032.34% in 2021, then soared by 73bps to 1642.1% in 2022, then soared by 36bps to 1048.32% in 2023, then plummeted by -282bps to 4007.83% in 2024, then plummeted by -1577bps to 67204.13% in 2025.
  • The last three reported values for EBT Margin were 67204.13% (Q4 2025), 7753.42% (Q2 2025), and 7740.43% (Q1 2025) per Business Quant data.